StreetInsider.com News Articles

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

Mon, 27 Jul 2026 07:00:00 -0400

NASHVILLE, Tenn., July 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the second quarter ended June 30, 2026, on Monday, August 10, 2026, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, August 11, 2026, to discuss the results and provide a business

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

Mon, 27 Jul 2026 07:00:00 -0400

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

Mon, 27 Jul 2026 07:00:00 -0400

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

Mon, 27 Jul 2026 07:00:00 -0400

Samsung Bioepis and Harrow share interim data on ranibizumab biosimilar

Mon, 20 Jul 2026 08:00:46 -0400

Samsung Bioepis Co., Ltd. and Harrow (NASDAQ: HROW) presented interim data from a post-marketing surveillance (PMS) study on SB11, a biosimilar referencing Lucentis (ranibizumab), at the 44th Annual Meeting of the American Society of Retina Specialists in Montréal, Canada.

The open-label, prospective, multicenter, observational Phase 4 study ran from May 2022 to May 2026 and was conducted in the Republic of Korea. The interim analysis included 298 of 305 enrolled patients, divided into 182 treatment-naïve and 116 switched patients. Patients were followed for up to 24 weeks after the first dose, with treatment intervals determined at the investigator's discretion.

Efficacy was measured

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Mon, 20 Jul 2026 08:00:00 -0400

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumab
In treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well maintained in patients who were switched from other anti-VEGF treatments to SB11, adding clinical confidence in using SB11

INCHEON, Korea and NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, presented interim data from a post-marketing surveillance (PMS) study on SB11

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Mon, 20 Jul 2026 08:00:00 -0400

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumab
In treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well maintained in patients who were switched from other anti-VEGF treatments to SB11, adding clinical confidence in using SB11

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Mon, 20 Jul 2026 08:00:00 -0400

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumab
In treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well maintained in patients who were switched from other anti-VEGF treatments to SB11, adding clinical confidence in using SB11

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Mon, 20 Jul 2026 08:00:00 -0400

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumab
In treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well maintained in patients who were switched from other anti-VEGF treatments to SB11, adding clinical confidence in using SB11

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Mon, 20 Jul 2026 08:00:00 -0400

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumab
In treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well maintained in patients who were switched from other anti-VEGF treatments to SB11, adding clinical confidence in using SB11

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Mon, 20 Jul 2026 08:00:00 -0400

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumab
In treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well maintained in patients who were switched from other anti-VEGF treatments to SB11, adding clinical confidence in using SB11

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Mon, 20 Jul 2026 08:00:00 -0400

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumab
In treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well maintained in patients who were switched from other anti-VEGF treatments to SB11, adding clinical confidence in using SB11

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Mon, 20 Jul 2026 08:00:00 -0400

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumab
In treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well maintained in patients who were switched from other anti-VEGF treatments to SB11, adding clinical confidence in using SB11

Harrow presents clinical data on two eye drugs at ASRS meeting

Mon, 20 Jul 2026 07:01:23 -0400

Harrow (Nasdaq: HROW) presented three studies on its ophthalmic products, IHEEZO and BYOOVIZ, at the American Society of Retina Specialists 2026 Annual Meeting, according to a company statement.

One study presented interim findings from a prospective, randomized trial of 150 patients comparing IHEEZO, a chloroprocaine HCl ophthalmic gel, against subconjunctival lidocaine. Investigators observed trends toward less post-procedure pain and fewer ocular symptoms through 24 hours following intravitreal injection among patients treated with IHEEZO. The findings are described as preliminary.

Harrow said it continues to enroll patients in QUELL, a prospective, randomized, multi-center clinical trial of approximately 236 subjects conducted under an active

Harrow presents clinical data on two eye drugs at ASRS meeting

Mon, 20 Jul 2026 07:01:23 -0400

Harrow (Nasdaq: HROW) presented three studies on its ophthalmic products, IHEEZO and BYOOVIZ, at the American Society of Retina Specialists 2026 Annual Meeting, according to a company statement.

Harrow said it continues to enroll patients in QUELL, a prospective, randomized, multi-center clinical trial of approximately 236 subjects conducted under an active

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting